title: Effects of transforming growth factor beta1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly(propylene fumarate) substrates.
abstract: Recombinant human transforming growth factor beta1 (TGF-beta1) was incorporated into microparticles of blends of poly(DL-lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) to create a delivery vehicle for the growth factor. The entrapment efficiency of TGF-beta1 in the microparticles containing 5% PEG was 40.3 +/- 1.2% for a TGF-beta1 loading density of 6.0 ng/1 mg of microparticles. For the same loading, 17.9 +/- 0.6 and 32.1 +/- 2.5% of the loaded TGF-beta1 was released after 1 and 8 days, respectively, followed by a plateau for the remaining 3 weeks. Rat marrow stromal cells showed a dose response to TGF-beta1 released from the microparticles similar to that of added TGF-beta1, indicating the activity of TGF-beta1 was retained during microparticle fabrication and after TGF-beta1 release. An optimal TGF-beta1 dosage of 1.0 ng/mL was determined through a 3-day dose response study for maximal alkaline phosphatase (ALP) activity. The TGF-beta1 released from the microparticles loaded with 6.0 ng TGF-beta1/1 mg of microparticles for the optimal dosage of TGF-beta1 enhanced the proliferation and osteoblastic differentiation of marrow stromal cells cultured on poly(propylene fumarate) substrates. The cells showed significantly increased total cell number, ALP activity, and osteocalcin production with values reaching 138,700 +/- 3300 cells/cm(2), 22.8 +/- 1.5 x 10(-7) micromol/min/cell, and 15.9 +/- 1.5 x 10(-6) ng/cell, respectively, after 21 days as compared to cells cultured under control conditions without TGF-beta1. These results suggest that controlled release of TGF-beta1 from the PLGA/PEG blend microparticles may find applications in modulating cellular response during bone healing at a skeletal defect site.
authors.affiliation: Departments of Bioengineering and Chemical Engineering, Rice University, Houston, Texas 77005-1892, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Peter
authors.forename: L
authors.initials: L
authors.lastname: Lu
authors.forename: D J
authors.initials: DJ
authors.lastname: Kim
authors.forename: G N
authors.initials: GN
authors.lastname: Stamatas
authors.forename: M J
authors.initials: MJ
authors.lastname: Miller
authors.forename: M J
authors.initials: MJ
authors.lastname: Yaszemski
authors.forename: A G
authors.initials: AG
authors.lastname: Mikos
mesh_terms: D000818:Animals; D001672:Biocompatible Materials; D002214:Capsules; D002478:Cells, Cultured; D016503:Drug Delivery Systems; D004343:Drug Implants; D005650:Fumarates; D006801:Humans; D019344:Lactic Acid; D010006:Osteoblasts / Q000187:drug effects*; D011092:Polyethylene Glycols; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011126:Polypropylenes; D051381:Rats; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: D001672:Biocompatible Materials; D002214:Capsules; D004343:Drug Implants; D005650:Fumarates; D011108:Polymers; D011126:Polypropylenes; D016212:Transforming Growth Factor beta; C097850:poly(propylene fumarate); D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols